Related Experiment Video

Updated: Jun 10, 2025

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

9.4K

GLP-1 Receptor Agonists Models for Type 1 Diabetes: A Narrative Review

Clara Furió-Novejarque1, José-Luis Díez1,2, Jorge Bondia1,2

  • 1Instituto Universitario de Automática e Informática Industrial, Universitat Politècnica de València, València, Spain.

Journal of Diabetes Science and Technology
|October 16, 2024
PubMed
Abstract

Insights

Mathematical models for glucagon-like peptide 1 (GLP-1) receptor agonists are needed for type 1 diabetes simulators. This review explores existing GLP-1 models to identify features for type 1 diabetes applications, highlighting a research gap.

Area of Science:

  • Biomedical Engineering
  • Endocrinology
  • Computational Biology

Background:

  • Glucagon-like peptide 1 (GLP-1) is a key hormone regulating glucose metabolism.
  • GLP-1 receptor agonists are established adjunctive therapies for type 2 diabetes.
  • Emerging interest exists in using GLP-1 receptor agonists with automated insulin delivery for type 1 diabetes.

Purpose of the Study:

  • To review and analyze existing mathematical models of GLP-1 effects.
  • To identify model features applicable to type 1 diabetes simulation.
  • To address the need for GLP-1 models in type 1 diabetes research.

Main Methods:

  • Systematic literature search across three databases.
  • Initial screening of over 1500 works based on keywords.
  • Full-text assessment of 39 selected works.

Main Results:

  • 23 works were identified detailing GLP-1 pharmacokinetics and pharmacodynamics.
  • No existing models were specifically designed for type 1 diabetes.
  • Analysis of transferable features from current models was performed.

Conclusions:

  • A significant gap exists in mathematical models for GLP-1 receptor agonists in type 1 diabetes.
  • Developing such models is crucial for creating type 1 diabetes simulators.
  • These simulators offer a safe and cost-effective platform for preclinical validation of GLP-1 therapies.
Keywords:
GLP-1mathematical modelpharmacodynamicspharmacokineticsreviewsimulation

More Related Videos

A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

12.7K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

535

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
142
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
178
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
173
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
163
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K